

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 8, 2018

XOMA CORPORATION
(Exact name of registrant as specified in its charter)

000-14710

(Commission
File Number)

Delaware

(State or other jurisdiction
of incorporation)

52-2154066

(IRS Employer
Identification No.)

2200 Powell Street, Suite 310, Emeryville, California

(Address of principal executive offices)

94608

(Zip Code)

Registrant's telephone number, including area code (510) 204-7200

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

Beginning on January 8, 2018, XOMA Corporation (the Company) will participate in conferences with investors and analysts during the 36th Annual JP Morgan Healthcare Conference in San Francisco, California. A copy of the Company's presentation materials has been posted to the Company's website and is attached hereto as Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, this information, including the Exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Current Report on Form 8-K will not be deemed an admission as to the materiality of any information that is required to be disclosed solely by Regulation FD.

Cautionary Statements

This filing and the presentation include "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Important factors that could impair the Company's royalty assets or business are disclosed in the "Risk Factors" contained in the Company's 2016 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 16, 2017, and updated in subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. We do not undertake any duty to update any forward-looking statement except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

XOMA CORPORATION

Date: January 8, 2018

/s/ James R.

Neal

James R. Neal

Chief Executive Officer



JANUARY 2018



Corporate Presentation

(Nasdaq: XOMA)

Forward-looking Statements

Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future monetization opportunities, active transactions with significant financial implications, collaborations poised for significant financial contribution, our library of value-generating assets, future potential for milestone and royalty payments, the potential of our unique antibody discovery engine, potential licensing of compounds in our endocrine asset pipeline, the prospects for our XOMA 213 asset for treatment of prolactinemia, the ability of our partners and their licensees to successfully develop their pipeline programs, the productivity of acquired assets that may not fulfill our revenue forecasts, upcoming internal milestones and value catalysts, our future cash needs, our strategy for value creation, and other statements that relate to future periods.

These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. Potential risks to XOMA meeting these expectations are described in more detail in XOMA's most recent filing on Form 10-K and in other SEC filings. Consider such risks carefully when considering XOMA's prospects. Any forward-looking statements represent XOMA's views only as of the date of this presentation and should not be relied upon as representing its views as of any subsequent date. XOMA disclaims any obligation to update any forward-looking statement, except as required by law.

XOMA: A De-risked way to Invest in Biotech



Growth Strategy



Allow extensive portfolio of fully-funded assets to mature to deliver milestones and royalties



Build size of portfolio through out-licensing and acquisition of fully-funded assets



Public listing provides capital access for company and liquidity for shareholders

Drive shareholder value by increasing size of portfolio to grow revenue potential and to mitigate risk while maintaining a lean cost structure

2017: A Transformational Year at XOMA

Expanded fully-funded portfolio with 9 new programs

Multiple milestone payments received – Novartis & Ology

Balance sheet re-capped
\$31M short-term debt eliminated; \$22M cash added


Dramatically reduced cost structure

Launched royalty aggregator strategy in March

**2017 was just
the beginning.**

We have built a foundation, and are now proceeding with a revolutionary plan to create shareholder value.

Nine New Fully-funded Programs Added in 2017



Novartis Transaction Underscores our Strategy

Build size of portfolio through out-licensing

- Gevokizumab out-licensed to Novartis
- IL-1 β IP portfolio out-licensed to Novartis

Strengthen balance sheet

- \$45M liquidity (cash + debt forgiveness), including \$5M equity investment

Grow revenue potential

- Up to \$438M gevokizumab milestones
- High-single to mid-teen gevokizumab royalties
- Single-digit canakinumab royalties in cardiovascular indications

Allow portfolio of assets to mature

- Over 4 years of projected cash
- No debt repayment until 2022



Out-licensed XOMA 358 & Phage Display Platform

XOMA 358

Licensed global development and commercialization rights to Rezolute

Up to \$240M in potential milestone payments

High single-digit to mid-teen royalties

Low single-digit royalties on net sales of other products developed by Rezolute

Phage Display Platform

Non-exclusive license agreements with Tizona Therapeutics, Torch Biosciences, and LakePharma

Potential development and regulatory milestone payments

Single-digit royalties

Example Value-Added Partnerships



anti-CD40 Antibody (CFZ533)

Multiple ongoing clinical studies
Milestones; tiered high-single digit to lower mid-teen royalties

TGFβ Antibody Program

\$480M potential milestones; tiered mid-single to low-double digit royalties
Phase 1

Antibody Discovery

Proprietary phage display library for antibody discovery
Potential milestones & single digit royalties

XOMA OUT-LICENSE

PHAGE DISPLAY PLATFORM


Broad Range of Partnerships



Sample of commercial products with XOMA IP held by others



Diversification in Biotech




The binomial distribution model captures the value of a diversified biotech portfolio which classical risk-adjusted, sum-of-the-parts NPV does not.

XOMA's portfolio of licensed assets are diversified across therapeutic areas and development stages.

As the size of the portfolio increases, so does the likelihood of success.

Diverse Portfolio Across Therapeutic Areas & Development Stages


THERAPEUTIC AREAS



DEVELOPMENT STAGES



Portfolio Driving Future Milestone and Royalties



Assets Available for Licensure

PROGRAM	DEVELOPMENT STAGE	INDICATION
IL-2	Preclinical	Immuno-oncology
XOMA 213	Phase 2	Various Hyperprolactinemias
XMetA	Preclinical	Diabetes & Rare Diseases
Anti-PTH1R	Preclinical	Hypercalcemia, Endocrine & Oncology

Accelerating Growth by Asset Acquisition

We intend to purchase the milestone and royalty obligations that are contractually associated with an underlying drug candidate

We DO NOT intend to acquire the underlying asset itself

We will differentiate from others in this approach by purchasing assets that are:

- Pre-commercial with clinical, regulatory, and commercial risk
- Deal size and payback period unattractive to lower cost of capital competitors
- Ideally, part of a basket to allow for multiple repayment possibilities

2017 Financial Highlights

Over **4 YEARS**
OF PROJECTED CASH

\$13M
MILESTONES EARNED

ELIMINATION OF
\$31M IN DEBT

SHARES OUTSTANDING
~8.2M **~13.3M**
BASIC INCLUDING
PREFERRED

LEAN COST STRUCTURE IN PLACE

2018 Business Objectives

Further expand portfolio of fully-funded programs

- Out-license proprietary programs & phage display platform
- Acquire additional fully-funded programs

Further strengthen balance sheet

Eliminate legacy expense structure

Enhance transaction capability to accelerate growth

XOMA: A De-risked way to Invest in Biotech





JANUARY 2018



Corporate Presentation

(Nasdaq: XOMA)
